THE BAUSCH & LOMB BRANDS YOU COUNT ON...



LOTEMAX°SM

(loteprednol etabonate ophthalmic gel) 0.38%

PROLENSA[®] (bromfenac ophthalmic solution) 0.07%

~70%

COVERAGE for Medicare Part D and commercial patients nationwide

- Medicare Part D coverage is unrestricted, without a latanoprost failure, step edit, or prior authorization (PA) needed*
- Commercial patients with CVS Caremark® and Express Scripts® require no PA*

*MMIT Analytics3, December 2022.

~9°F10

VYZULTA PRESCRIPTIONS

have been approved by Medicare Part D and commercial insurance plans[†]

†IQVIA FIA data, December 2021-November 2022. Medicare Part D: 93%, commercial: 90%.

VYZULTA COPAY MAY BE
AS LITTLE AS \$25
FOR 30-, 60-, OR
90-DAY SUPPLY

Prescriptions approved by Medicare Part D and commercial insurance plans

~87%

~85%

Patients with UNRESTRICTED ACCESS nationwide (no PA or step edits needed)

~139M"

~114M"

Unrestricted Medicare plans for both LOTEMAX® SM and PROLENSA® include: UnitedHealthcare/AARP®, CVS (SilverScript), Express Scripts (ESI), Cigna®, and other national and regional plans

Unrestricted commercial plans for both LOTEMAX® SM and PROLENSA® include: OptumRx®, Anthem®, Cigna, Federal Employee Health Benefits (FEHB), and other national and regional plans

Most eligible Medicare Part D patients

MAY PAY AS LITTLE AS \$80 on each prescription



SCAN QR CODE TO ACTIVATE BAUSCH & LOMB PART D COUPON

These products have not been approved for concomitant use. For approved indications, safety information, and full Prescribing Information, please go to www.lotemaxsm.com and www.prolensarx.com.

[§]IQVIA data, January 2022-May, 2022. Medicare Part D approval rates: LOTEMAX* SM 86.5%, PROLENSA*: 84.8%. Commercial approval rates: LOTEMAX* SM 87.0%, PROLENSA*: 87.1%.

MMIT Formulary Status, December 2022. LOTEMAX* SM: Medicare Part D: 32M, commercial: 107M. PROLENSA*: Medicare Part D: 35M, commercial: 79M.

Terms, condition and limitations apply. Please see eligibility criteria and terms and conditions at bauschlombpartd. copysavingsprogram.com. For questions call: 1-800-795-1091.

For VYZULTA, LOTEMAX SM, and PROLENSA—

Eligible commercially insured patients MAY PAY AS LITTLE AS:





For patients who qualify for Low-Income Subsidy,

THE COPAY IS LESS THAN \$11"

Terms, conditions, and limitations apply. Available exclusively at Walgreens and other participating independent pharmacies. At non-participating pharmacies, eligible patients may pay as little as a \$35 copay. Please see eligibility criteria and terms and conditions at BauschAccessProgram.com. For VYZULTA, 90-day supply to be prescribed as 3 bottles of 2.5 mL solution each. 90-day VYZULTA supply copay offer only applies if each of the three 2.5 mL bottles is covered by the patient's commercial insurance.

*Centers for Medicare & Medicaid Services, 2022.



PHARMACY RESOLUTION GUIDE

The Pharmacy Resolution Guide is intended to provide office staff with helpful information when they encounter callback issues from the pharmacy.

PROACTIVELY ADDRESS THE 3 MOST COMMON REASONS FOR A PHARMACY CALLBACK

1. COVERAGE

"The prescription isn't covered."

- Was the insurance card run?
- What are you hearing from the patient?
- What do you show for the drug benefit plan? Is it commercial?
- Do you take their drug benefit plan? Or are you just running their medical insurance?
- Was the Bausch + Lomb Access Program copay card run?

2. COST

"The medication prescribed is too expensive."

- Was the insurance card run?
- Did you provide a Bausch + Lomb Access Program copay card?
 - If yes, what cost was quoted?
- For VYZULTA, is the price being quoted for a 30-60-90-day supply?

Scan this QR code for VYZULTA Access
Program support and resources, including
PA support and Medical Necessity or
Tier Exception forms



3. AVAILABILITY

"The medication prescribed is not in stock/unavailable."

- Can the prescribed product be ordered and sent to the pharmacy?
 - If so, when can it be delivered?
- Can you check availability at another pharmacy?
- Can you send to another pharmacy?

